White & Case Is Advising Anacor Pharmaceuticals on Its Pending US$5.2 Billion Acquisition by Pfizer Inc.
Global law firm White & Case LLP is advising Anacor Pharmaceuticals (NASDAQ:ANAC), as antitrust counsel, in its pending US$5.2 billion acquisition by Pfizer Inc. (NYSE:PFE).
Anacor, a Palo Alto, CA-based biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform, is expected to be acquired for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of approximately US$5.2 billion.
The transaction, which is subject to customary closing conditions and antitrust clearance, is expected to close the third-quarter of 2016.
The White & Case team is led by partners J. Mark Gidley, Rebecca Farrington, Noah Brumfield, and associates Lynn Diamond, Jaclyn Epstein, and Lee Czocher.
For more information, please speak to your local media contact.